HGH Fragment 176–191 is a synthetic peptide derived from the C-terminal amino acid sequence (176–191) of human growth hormone (HGH). This fragment was identified as the region of HGH responsible for its fat-burning properties, while excluding the sections that promote growth, muscle gain, or significant hormonal activity.
HGH Fragment 176–191 works by stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation of new fat). It enhances the release of free fatty acids from adipose tissue, making them available for energy use, while helping reduce fat accumulation. Unlike full-length HGH, this peptide does not significantly affect IGF-1 levels, insulin sensitivity, blood glucose, or cell growth pathways.
Because of its targeted mechanism, HGH Fragment 176–191 is considered non-anabolic and non-androgenic, meaning it does not promote muscle hypertrophy, bone growth, or organ enlargement. This selective action contributes to its favorable safety profile compared to traditional growth hormone therapies.
Originally researched for obesity and metabolic health, HGH Fragment 176–191 demonstrated promising results in both animal and early human studies, showing reductions in body fat and improvements in fat metabolism. It is commonly used in research and wellness-focused applications aimed at supporting weight management and body composition.
HGH Fragment 176–191 is not approved as a prescription medication in most regions and is typically marketed for research purposes. Reported side effects are generally mild and uncommon, particularly when compared to full HGH use.
In summary, HGH Fragment 176–191 is a specialized fat-loss peptide designed to enhance fat metabolism without the growth-related or hormonal effects associated with human growth hormone.
